Aclaris Therapeutics reported a narrower-than-expected net loss for the third quarter of 2026, driven by disciplined research spending and a gain from the revaluation of contingent consideration. While revenue fell short of estimates due to the timing of licensing milestones, the company significantly strengthened its balance sheet, extending its projected cash runway by two years into the first half of 2029.
Key Highlights
- Net loss of $18.5 million, or $0.12 per share, outperformed the consensus estimate of a $0.16 per share loss.
- Total revenue of $1.5 million missed the $5.6 million estimate, declining from $3.3 million in the prior year period due to one-time milestones recognized in 2025.
- Cash and marketable securities reached $204.6 million as of September 30, further bolstered by $50.0 million in gross proceeds from an October 2026 equity offering.
- Clinical development remains on track with the Phase 2b trial for modzatinib in lichen planus expected to initiate in the fourth quarter of 2026.